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Abstract
Acquired resistance to classical chemotherapeutics is a major obstacle in cancer treatment. Doxorubicin is frequently used
in breast cancer therapy either as single-agent or in combination with other drugs like docetaxel and cyclophosphamide. All
these chemotherapies have in common that they are administered sequentially and often result in chemoresistance. Here,
we mimicked this pulse therapy of breast cancer patients in an in vitro cell culture model, where the epithelial breast cancer
cell line BT474 was sequentially treated with doxorubicin for several treatment cycles. In consequence, we obtained
chemoresistant cells displaying a mesenchymal-like phenotype with decreased levels of miR-200c. To investigate the
involvement of miR-200c in resistance formation, we inhibited and overexpressed miR-200c in different cell lines. Thereby,
the cells were rendered more resistant or susceptible to doxorubicin treatment. Moreover, the receptor tyrosine kinase TrkB
and the transcriptional repressor Bmi1 were identified as miR-200c targets mediating the drug resistance. Hence, we
provide a mechanism of acquired resistance to doxorubicin that is caused by the loss of miR-200c. Along with this, our study
demonstrates the complex network of microRNA mediated chemoresistance highlighting the challenges in cancer therapy
and the importance of novel microRNA-modulating anticancer agents.
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Introduction
Breast cancer is the most common malignancy in women with
230000 estimated new cases and 40000 estimated deaths in the
United States in 2012 [1]. Even though early detection methods
and treatment options greatly improved due to a better un-
derstanding of the underlying molecular mechanisms, resistance to
classical chemotherapeutics is still a tremendous challenge for
breast cancer therapy. About 30% of all breast cancer patients
who are successfully treated at early stages are suffering a relapse
accompanied by metastasis and chemoresistance to classical drugs
[2,3]. While the response rates for first-line chemotherapy
including anthracyclines and taxanes are up to 70%, the response
rate falls to only 20 to 30% after disease progression. Besides
metastasis, this acquired chemoresistance is a major obstacle in the
treatment of breast cancer [4,5]. Hence, an advancement of the
treatment by avoiding drug resistance and a better prediction of
chemotherapy efficacy would improve the clinical outcome for
breast cancer patients.
microRNAs are endogenous, non-coding RNAs of approxi-
mately 22 nucleotides that target various genes either by degrading
the mRNA or by repressing the translation [6,7]. Moreover,
microRNAs are shown to be dysregulated in many cancers, such
as breast, prostate, colon and lung. Thereby, microRNAs can
function as onco-miRs or tumor-suppressor-miRs depending on
their respective target genes [8,9]. Previous studies have also
shown that microRNAs are able to modulate the sensitivity of
cancer cells to chemotherapeutic drugs and therefore contribute to
the acquisition of chemoresistance [10,11,12,13,14].
miR-200c has been reported to regulate epithelial to
mesenchymal transition (EMT) by targeting the transcriptional
E-Cadherin repressors Zeb1 and Zeb2 [15,16,17]. Thus, high
miR-200c levels determine an epithelial phenotype of cancer
cells which is defined by an elevated E-Cadherin expression,
a low migratory capacity and a cobble-stone-like cell morphol-
ogy [18,19,20]. Recent findings suggest that loss of miR-200c
may regulate resistance to chemotherapeutics, such as paclitaxel
or cisplatin [21,22]. However, an exact mechanism of miR-200c
dependent acquired chemoresistance had yet to be elucidated.
In this study, we mimicked the sequential doxorubicin
treatment of breast cancer in an in vitro cell culture system using
the epithelial breast cancer cell line BT474. The repeated
treatment with doxorubicin resulted in a molecular evolution of
the tumor cells accompanied by the acquisition of a mesenchy-
mal-like and chemoresistant phenotype which was characterized
by a significant down-regulation of miR-200c. Furthermore, we
proved in two different breast cancer cell lines that either
inhibition or overexpression of miR-200c was sufficient to
increase doxorubicin resistance or susceptibility, respectively.
Finally, TrkB and Bmi1 were identified as two miR-200c target
genes responsible for the acquisition of chemoresistance. Thus,
the study provides new insights into the complex regulation of
acquired chemoresistance caused by the down-regulation of miR-
200c.
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Materials and Methods
Primary Antibodies
E-Cadherin (C20820, Transduction Laboratories); Vimentin
(V9) (SC-6260, Santa Cruz); TrkB (H-181) (SC-8316, Santa Cruz);
Akt (#9272, Cell Signaling); p-Akt (S-473) (#4051, Cell Signal-
ing); Bmi1 (PAI-16973, Thermo Scientific); p53 (DO-1) (SC-126,
Santa Cruz), Actin (I-19) (SC-1616, Santa Cruz); a-Tubulin (DM-
1A) (T9026, Sigma).
Cell Culture
The breast cancer cell lines BT474 and MDA-MB 436 were
obtained from Cell Line Services (Eppelheim, Germany) and
cultivated according to supplier’s instructions. Briefly, BT474 cells
were grown in RPMI 1640 medium (Gibco) supplemented with
10% fetal calf serum (FCS) and 2 mM glutamine (Gibco) at 37uC
and 5% CO2. MDA-MB 436 cells were cultivated in L-15
Leibovitz medium (Biochrom) supplemented with 10% FCS and
2 mM glutamine at 37uC without CO2.
Molecular Evolution Assay
The epithelial breast cancer cell line BT474 was treated with
50 nM doxorubicin (doxorubicin hydrochloride, Sigma) for 72
hours when cells reached a confluency of 80%. After treatment
doxorubicin containing medium was replaced by fresh medium.
As soon as cells recovered, they were seeded for RNA isolation,
cell lysis (protein), cytotoxicity assays and the next treatment cycle.
In this manner four rounds of the Molecular Evolution Assay were
performed. To obtain the appropriate rate of cell death in the
Molecular Evolution Assay, several doxorubicin concentrations
were tested in a preliminary experiment. Thereby, 50 nM was
obtained as the most suitable concentration.
For cytotoxicity assays 5000 cells were seeded in 96-well plates
after each round of the Molecular Evolution Assay. 24 hours after
seeding cells were treated with different concentrations of
doxorubicin for 72 hours. After incubation a CellTiter Glo assay
(Promega) was performed following manufacturer’s instructions.
Quantitative RT-PCR
For mRNA quantification total RNA was isolated with the
miRCURY RNA Isolation Kit (Exiqon) followed by a reverse
transcription using Transcriptor High Fidelity cDNA Synthesis Kit
(Roche) according to manufacturers’ protocols. Quantitative RT-
PCRwasperformedonaLightCycler 480 system (Roche) usingUPL
Probes (Roche) and Probes Master (Roche). Genes of interest were
normalized to GAPDH as reference using the DCT method. The
following probes andprimer sequenceswere used:E-Cadherin,UPL
Probe #35, left primer: CCCGGGACAACGTTTATTAC, right
primer: GCTGGCTCAAGTCAAAGTCC;TrkB,UPLProbe#2,
left primer: AGTGCCTCTCGGATCTGGT, right primer:
TTTCTGGTTTGCGATGAAAAT; Bmi1, UPL Probe #54, left
primer: TGTAAAACGTGTATTGTTCGTTACC, right primer:
CAATATCTTGGAGAGTTTTATCTGACC; GAPDH, UPL
Probe #60, left primer: AGCCACATCGCTCAGACAC, right
primer: GCCCAATACGACCAAATCC.
For microRNA quantification total RNA was isolated with the
miRCURY RNA Isolation Kit. cDNA synthesis was carried out by
a microRNA specific reverse transcription using Transcriptor High
Fidelity cDNA Synthesis Kit and a stem loop primer (SLP) which
was specific for only one particular microRNA [23,24,25].
Quantitative RT-PCR was then performed on a LightCycler 480
systemusing SYBRGreen IMaster (Roche). The expression ofmiR-
200 family members (miR-141, miR-200a, miR-200b, miR-200c,
miR-429) was normalized to miR-191 as reference [26] using the
DCT or DDCT method. All sequences of the primers used for the
microRNA quantification are shown in the supplement (Table S1).
miR-200c Inhibition
BT474 and MDA-MB 436 cells were seeded in 96-well plates at
a density of 3000 cells per well. The following day cells were
transfected with 50 nM miRCURY LNA microRNA Inhibitor for
hsa-miR-200c (miR-200c inhibitor) (Exiqon) or miRCURY LNA
microRNA Inhibitor Control Negative Control A (scrambled
control) (Exiqon) using Lipofectamine 2000 (Invitrogen) according
to manufacturer’s protocol.
24 hours after transfection cells were treated with different
concentrations of doxorubicin for 72 hours followed by a CellTiter
Glo assay.
miR-200c Overexpression
MDA-MB 436 and BT474 cells were transfected in 6-well plates
with 100 pmol Pre-miR miRNA Precursor of hsa-miR-200c (pre-
miR-200c) (Ambion) or Pre-miR miRNA Negative Control
(scrambled control) (Ambion) using Lipofectamine 2000 according
to manufacturer’s protocol. After three consecutive transfections
cells were harvested for RNA isolation, cell lysis (protein) and
cytotoxicity assays.
For cytotoxicity experiments transfected cells were plated on 96-
well plates at a density of 3000 cells per well. 24 hours after seeding
cells were treated with different concentrations of doxorubicin for
72 hours followed by a CellTiter Glo assay.
Cell Lysis and Immunoblotting
Cells werewashedwith PBS and incubated at 4uCwith lysis buffer
(Promega) supplemented with phosphatase and protease inhibitors
(Santa Cruz and Roche). Cellular debris was removed by
centrifugation. Protein estimation was performed using the Micro
BCA Protein Assay Kit (Thermo Scientific). Samples were
suspended in SDS sample buffer containing b-mercaptoethanol,
boiled for 5 minutes and subjected to SDS-PAGE. For western blot
analysis, proteins were transferred to nitrocellulose membranes and
incubated with the appropriate antibodies. Signals were developed
using either Peroxidase Horse Anti-Rabbit IgG Antibody or
Peroxidase Goat Anti-Mouse IgG Antibody (Vector Laboratories)
and Lumi-LightPLUS Western Blotting Substrate (Roche). Western
blot quantification was carried out using ImageJ software [27].
Immunofluorescence
Cells were seeded on a cover slip and fixed with 4% para-
formaldehyde. Cover slips were blockedwith 10%FCS, 1%gelatine
and 0.05% Triton X-100 and incubated with indicated primary
antibodies. Immunofluorescence was visualized using Donkey anti-
Mouse IgG (Cy3) (PA1-29773, Thermo Scientific). Counterstaining
was performed using 49-6-diamidino-2-phenylindole (DAPI) (Sig-
ma). Results were analyzed using Zeiss Laser Scanning Microscope
LSM 510 Meta and Axiovert 200 software (Zeiss).
Results
Molecular Evolution of Breast Cancer Cells Leads to
a Chemoresistant Phenotype and Down-regulation of
miR-200c
Occurrence of chemoresistance is one of the major obstacles in
chemotherapy of breast cancer patients. Thus, we wanted to
mimic the pulse therapy of cancer patients applied in the clinics by
using an in vitro cell culture system. Therefore, we established the
Molecular Evolution Assay, where we treated the epithelial breast
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cancer cell line BT474 with doxorubicin for several cycles
(Figure 1A). After each treatment round cells were harvested for
cytotoxicity assays as well as RNA and protein isolation to
investigate changes in chemosensitivity and gene expression. The
cytotoxicity assays revealed that cells became more resistant from
the third treatment cycle on. This effect did not get more
significant after the fourth treatment round indicating that the
chemoresistant phenotype was obtained within three treatments
(Figure 1B). In addition, we could see a change in cell morphology
from cobble-stone shape to cells showing slightly more scattering
and cytoplasmic processes (Figure 1C). To further characterize the
altered phenotype of the doxorubicin treated cells, the protein
expressions of E-Cadherin and Vimentin were determined in the
rounds of the Molecular Evolution Assay. In accordance with the
microscopic pictures, we observed a decrease of E-Cadherin and
an increase of Vimentin suggesting an EMT-like mechanism
Figure 1. Molecular evolution of breast cancer cells leads to a chemoresistant phenotype and down-regulation of miR-200c. A)
Molecular Evolution Assay. The epithelial breast cancer cell line BT474 was sequentially treated with chemotherapy. Cells were treated with 50 nM
doxorubicin for 72 hours. Subsequently, medium was replaced by fresh medium until cells recovered and reached a confluency of 80%. Finally, cells
were splitted for RNA isolation, cell lysis (protein), cytotoxicity assays and the next treatment round. R0 represents the untreated control cell line,
whereas R1, R2, R3 and R4 represents BT474 cells that are treated for one, two, three and four times, respectively. B) Susceptibility to doxorubicin
treatment. BT474 cells of R1 to R4 were treated with 0.1 and 10 mM doxorubicin for 72 hours. A CellTiter Glo assay was carried out to determine cell
viability. Results are indicated as percentage of viable cells normalized to mock treated cells. C) Cell morphology of untreated and treated BT474 cells.
Microscopic pictures (phase contrast) were taken from untreated BT474 cells (R0) and from doxorubicin treated and recovered cells of R4. D) Epithelial
and mesenchymal marker expression in BT474 cells of R0, R2 and R4 of the Molecular Evolution Assay. E-Cadherin and Vimentin protein levels were
determined by western blot analysis. Actin was used as loading control. E) miR-200c expression in BT474 cells that have undergone molecular
evolution. Quantitative RT-PCR was performed to analyze miR-200c levels in BT474 cells of R1 to R4. miR-200c expression was thereby normalized to
miR-191. Results are depicted as fold expression compared to the untreated control cell line (R0). Experiments were done in triplicates. For statistical
analysis a student’s t-test was performed. (*p,0.05; **p,0.01; ***p,0.001).
doi:10.1371/journal.pone.0050469.g001
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(Figure 1D). As the miR-200 family is regulating EMT by
inhibiting transcriptional repressors of E-Cadherin [16,17,28,29],
we analyzed the expression levels of all family members (miR-141,
miR-200a, miR-200b, miR-200c and miR-429) in BT474 cells.
Thereby, miR-200c was the most abundantly expressed family
member showing a more than 10-fold higher expression (Figure
S1). Hence, we investigated the miR-200c levels during the
Molecular Evolution Assay and observed a significant down-
regulation within three rounds without any further decrease after
the fourth treatment (Figure 1E).
Figure 2. Characterization of the epithelial and the mesenchymal breast cancer cell line BT474 and MDA-MB 436. A) miR-200c levels in
a panel of mesenchymal (MDA-MB 436, MDA-MB 231, MDA-MB 157) and epithelial (MCF-7, MDA-MB 468, BT474) breast cancer cell lines. Quantitative
RT-PCR was performed to assess the levels of miR-200c. Expression was normalized to miR-191 and presented as ratio. B) Epithelial and mesenchymal
phenotype of BT474 and MDA-MB 436 cells. To confirm the different phenotypes, microscopic pictures were taken from both cell lines (phase
contrast, left panel). Furthermore, immunofluorescence and laser scanning microscopy was carried out to determine E-Cadherin (red, middle panel)
and Vimentin (red, right panel) expression. Nuclei were stained with DAPI (blue). C) Dose reponse curves and IC50 values for doxorubicin. BT474 and
MDA-MB 436 cells were treated with different concentrations of doxorubicin for 72 hours. Subsequently, a CellTiter Glo assay was performed to
determine the percentage of viable cells (normalized to mock treated cells). IC50 values are shown in the table. Experiments were done in triplicates.
For statistical analysis a student’s t-test was performed. (***p,0.001).
doi:10.1371/journal.pone.0050469.g002
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Characterization of the Epithelial and the Mesenchymal
Breast Cancer Cell Line BT474 and MDA-MB 436
To investigate the role of miR-200c in chemoresistance, a panel
of different breast cancer cell lines was tested for the abundance of
miR-200c. The mesenchymal cell lines (MDA-MB 436, MDA-MB
231 and MDA-MB 157) showed no expression of miR-200c,
whereas the epithelial cell lines (MCF-7, MDA-MB 468 and
BT474) displayed high levels of miR-200c (Figure 2A). The cell
line with the highest miR-200c expression (BT474) and one with
no miR-200c expression (MDA-MB 436) were further character-
ized.
Consistent with the miR-200c expression, BT474 cells grew in
clusters with tight cell-cell junctions representing an epithelial cell
type, whereas MDA-MB 436 cells grew as single, spindle-shaped
cells resembling a mesenchymal morphology (Figure 2B) [30].
Immunofluorescence confirmed the epithelial phenotype of
BT474 in terms of high membrane localized E-Cadherin and
low cytoplasmic Vimentin expression. On the other hand, MDA-
MB 436 exhibited high Vimentin and only low E-Cadherin levels
(Figure 2B) [30]. Finally, we determined the IC50 values for
doxorubicin in BT474 and MDA-MB 436. Dose response curves
revealed that BT474 cells were approximately 22-fold more
susceptible to doxorubicin treatment compared to MDA-MB 436
cells (Figure 2C).
Thus, BT474 represents an epithelial breast cancer cell line with
high levels of miR-200c and E-Cadherin. On the contrary, MDA-
MB 436 displayed a mesenchymal phenotype with no expression
of miR-200c, but with a high expression of the mesenchymal
marker Vimentin. Along with these findings, BT474 cells were
significantly more susceptible to doxorubicin treatment compared
to MDA-MB 436 cells. These two cellular systems enabled us to
investigate the role of miR-200c in chemoresistance by either
inhibiting or overexpressing this particular microRNA.
Inhibition of miR-200c in BT474 Cells Causes
Chemoresistance to Doxorubicin Treatment
We wanted to prove the direct involvement of miR-200c in
regulating chemosensitivity. Hence, BT474 and MDA-MB 436
cells were transfected with a miR-200c inhibitor (a locked nucleic
acid (LNA) antisense molecule) as well as a scrambled control. As
MDA-MB 436 cells have no miR-200c expression, this cell line
served as a control to exclude off-target effects of the used LNAs.
By transfecting BT474 cells with the miR-200c inhibitor, we
observed significantly reduced levels of miR-200c compared to
those cells transfected with the scrambled control (Figure 3A).
miR-200c inhibition in BT474 cells also resulted in a more
elongated and spindle-shaped cell morphology (Figure 3B). There
was no change in cell morphology in MDA-MB 436 cells (data not
Figure 3. Inhibition of miR-200c in BT474 cells causes chemoresistance to doxorubicin treatment. A) miR-200c expression after
inhibiton. 24 hours after transfection with either miR-200c inhibitor or scrambled control, BT474 cells were harvested for RNA isolation and
quantitative RT-PCR. miR-200c expression was normalized to miR-191 and presented as ratio. B) Cell morphology. Micrographs (phase contrast) of
BT474 cells were taken 24 hours after transfection with either miR-200c inhibitor or scrambled control. C) Susceptibility to doxorubicin treatment.
BT474 and MDA-MB 436 cells, transfected with inhibitor or scrambled control, were treated with 1, 10 and 20 mM doxorubicin for 72 hours. Cell
viability was analyzed using CellTiter Glo. Experiments were done in triplicates with at least two biological replicates. For statistical analysis a student’s
t-test was performed. (ns = not significant; *p,0.05; **p,0.01; ***p,0.001).
doi:10.1371/journal.pone.0050469.g003
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shown). Most notably, the transfection of BT474 cells with miR-
200c inhibitor resulted in significantly more resistant cells, when
treated with doxorubicin. As expected, there was no significant
effect observable in MDA-MB 436 cells (Figure 3C).
Overexpression of miR-200c in MDA-MB 436 Cells
Increases Susceptibility to Doxorubicin
As demonstrated, miR-200c inhibition in BT474 cells resulted
in chemoresistance to doxorubicin. Hence, we investigated
whether it was possible to sensitize the miR-200c negative and
doxorubicin resistant cell line MDA-MB 436 to doxorubicin
treatment by overexpressing miR-200c. Thus, we transfected
MDA-MB 436 cells with a microRNA-200c precursor (pre-miR-
200c) and gained a high ectopic overexpression of miR-200c
(Figure 4A). In accordance with previous studies [15,16,18,19],
cell morphology of pre-miR-200c transfected cells changed to
a more epithelial-like phenotype with cells growing in clusters
(Figure 4B). Finally, we performed a cytotoxicity assay to
investigate whether the miR-200c overexpressing cells were more
susceptible to doxorubicin treatment. In all doxorubicin concen-
trations the miR-200c overexpressing cells displayed a higher
sensitivity to the treatment. On the other hand, susceptibility of
BT474 cells did not increase by further overexpressing miR-200c
(Figure 4C).
TrkB and Bmi1 Protein Expression is Hampered by
Overexpression of miR-200c in MDA-MB 436 Cells
microRNAs regulate gene expression endogenously either by
degrading mRNA or mainly by inhibiting the translational
process. Therefore, biological functions and physiological effects
of microRNAs can be directly attributed to the silencing of their
particular target genes. Thus, we searched for candidates that are
targeted by miR-200c and can interfere with cell survival or
chemoresistance.
Howe et al. [31] have recently reported that TrkB (NTRK2),
a member of the neurotrophic tyrosine receptor kinase family, is
a direct target of miR-200c and responsible for anoikis resistance
in breast cancer. It has also been shown that in neurons TrkB is
involved in differentiation, proliferation and particularly in
survival [32].
To clarify if TrkB can be silenced in the cell line MDA-MB 436
upon miR-200c overexpression, we transfected MDA-MB 436
cells with pre-miR-200c or scrambled control. As expected, the
protein expression of two TrkB isoforms (gp145 and gp95) was
decreased in pre-miR-200c transfected cells compared to scram-
bled control transfected cells (Figure 5A). On the contrary, TrkB
mRNA levels were not altered suggesting that TrkB translation
was repressed by miR-200c without degradation of the mRNA
(Figure 5B). The receptor tyrosine kinase TrkB is signaling
amongst other pathways via PI3K and Akt [32], which plays
Figure 4. Overexpression of miR-200c in MDA-MB 436 cells increases susceptibility to doxorubicin. A) miR-200c levels after
overexpression. After three consecutive transfections with either pre-miR-200c or scrambled control, MDA-MB 436 cells were harvested for RNA
isolation and quantitative RT-PCR. miR-200c expression was normalized to miR-191 and presented as ratio. B) Cell morphology. Micrographs (phase
contrast) of MDA-MB 436 cells were taken after three consecutive transfections with either pre-miR-200c or scrambled control. C) Susceptibility to
doxorubicin treatment. With pre-miR-200c or scrambled control transfected MDA-MB 436 and BT474 cells were treated with 1, 5 and 10 mM
doxorubicin for 72 hours. Cell viability was determined by a CellTiter Glo assay. Experiments were done in triplicates with at least two biological
replicates. For statistical analysis a student’s t-test was performed. (ns = not significant; *p,0.05; **p,0.01; ***p,0.001).
doi:10.1371/journal.pone.0050469.g004
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a pivotal role in cell survival. Thus, we analyzed the phosphor-
ylation status of Akt. However, there were no detectable
differences in the p-Akt levels of pre-miR-200c and scrambled
control transfected cells. Hence, we treated pre-miR-200c as well
as scrambled control transfected MDA-MB 436 cells with
doxorubicin for 24 hours to induce Akt dependent survival
signaling. Here, we observed enhanced phosphorylation of Akt in
the scrambled control transfected cells, whereas miR-200c over-
expressing cells still showed low levels of p-Akt (Figure 5C).
Figure 5. TrkB and Bmi1 protein expression is hampered by overexpression of miR-200c in MDA-MB 436 cells. Total cell lysates of pre-
miR-200c (pre) and scrambled control (scr) transfected MDA-MB 436 cells were subjected to western blot analysis and quantitative RT-PCR to
determine expression of A) TrkB (gp145 and gp95) protein, B) TrkB mRNA C) p-Akt protein either after treatment with 0.5 mM doxorubicin for 24
hours (right panel) or untreated (left panel), D) Bmi1 protein, E) Bmi1 mRNA and F) p53 protein. a-Tubulin or Actin was used as loading control.
Western blot quantification of three independent experiments was carried out by analyzing the relative intensities (rel. int.) of TrkB or Bmi1
normalized to the rel. int. of a-Tubulin or Actin using ImageJ software. For quantitative RT-PCR TrkB and Bmi1 expressions were normalized to GAPDH
as reference and presented as ratio. A student’s t-test was performed to assess statistical significance. (ns = not significant; *p,0.05)
DXR=doxorubicin.
doi:10.1371/journal.pone.0050469.g005
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Another target of miR-200c is Bmi1, a regulator of stem cell
self-renewal and senescence [33]. It has been reported that Bmi1
confers cisplatin and docetaxel resistance in osteosarcoma and
prostate cancer, respectively [34,35]. Thus, we transfected either
pre-miR-200c or scrambled control into the mesenchymal cell line
MDA-MB 436. As hypothesized, Bmi1 was silenced in the pre-
miR-200c transfected cells compared to the scrambled control
transfected cells (Figure 5D). Consistent with TrkB, Bmi1 mRNA
was also not degraded by miR-200c (Figure 5E). Bmi1 functions as
transcriptional repressor leading to the repression of a variety of
genes including p16Ink4a and p19Arf of the Ink4a locus. Since
repression of p19Arf results in the degradation of p53 by MDM2
leading to anti-apoptotic effects [36], we determined p53 protein
expression in pre-miR-200c transfected cells. However, no
regulation of p53 protein was observed in MDA-MB 436 as this
cell line lacks intrinsic p53 (Figure 5F).
The Protein Expression of TrkB and Bmi1 is Regulated
during the Rounds of the Molecular Evolution Assay in
BT474 cells
After demonstrating the effects of miR-200c on the target genes
TrkB and Bmi1, we analyzed whether these proteins are also
regulated in the Molecular Evolution Assay.
BT474 cells showed a slight elevation of TrkB in the second
round (R2) followed by a down-regulation in the last round (R4)
(Figure 6A). Moreover, we determined the phosphorylation status
of Akt, a downstream target of TrkB and an important regulator of
cell survival. Consistent with the regulation of TrkB expression, p-
Akt was considerably increased in round 2 (R2) and decreased in
round 4 (R4) (Figure 6B).
We also analyzed Bmi1 levels in the protein lysates of the
Molecular Evolution Assay of BT474 cells. An up-regulation of
Bmi1 was observed with no protein expression in the control
round (R0), a slight expression in the second (R2) and a high
expression in the fourth round (R4) (Figure 6C). Consequently, we
analyzed protein expression of p53 and observed a decline of p53
in round 4 (R4) (Figure 6D). We showed that the Molecular
Evolution Assay of BT474 cells led to a regulation of TrkB and
Bmi1 protein expression. The respective downstream targets, p-
Akt and p53, were modulated accordingly conferring the observed
chemoresistance.
Discussion
In breast cancer treatment classical chemotherapy is largely
used besides hormone therapy and novel targeted therapy
approaches [4,37]. For instance, the anthracycline doxorubicin
(AdriamycinH) is commonly used as single-agent or in combination
with other drugs like docetaxel (TaxotereH) and cyclophosphamide
(TAC regimen) in an adjuvant or neo-adjuvant setting [38].
Generally, chemotherapy regimens are administered sequentially,
i.e. in case of the TAC regimen patients are treated six times every
three weeks [39,40]. In our study, we mimicked this pulse
chemotherapy of breast cancer in an in vitro cell culture model by
treating the epithelial breast cancer cell line BT474 sequentially in
four cycles with doxorubicin. The treatment of BT474 cells with
a recovery phase followed by the next treatment cycle resembles
the therapy regimen in patients and thereby provides a model for
acquired chemoresistance. Indeed, we demonstrated for the first
time that Molecular Evolution Assay of BT474 resulted in
significantly more resistant cells within three treatment cycles.
Acquisition of chemoresistance was accompanied by a change in
cell morphology and in the expression of the epithelial marker E-
Cadherin and the mesenchymal marker Vimentin suggesting that
an EMT-like mechanism might be involved. Besides the well
investigated and established regulation of EMT [9,15,16,41],
recent findings also suggest that the loss of miR-200c regulates
resistance to paclitaxel or cisplatin [18,21,22]. However, an exact
mechanism of miR-200c dependent acquired chemoresistance had
to be elucidated. Here, we show that the sequential doxorubicin
treatment of the epithelial breast cancer cell line BT474 leads to an
altered phenotype with decreased miR-200c levels resulting in
doxorubicin resistance.
To further investigate the role of miR-200c in acquired
chemoresistance, we utilized two different cell lines, where we
were able to modulate chemoresistance by molecular manipula-
tion of the respective miR-200c levels. First, we inhibited the miR-
Figure 6. The protein expression of TrkB and Bmi1 is regulated during the rounds of the Molecular Evolution Assay in BT474 cells.
Total cell lysates of BT474 cells derived from R0, R2 and R4 of the Molecular Evolution Assay were subjected to western blot analysis to determine
protein expression of A) TrkB isoforms, B) p-Akt, C) Bmi1 and D) p53. Actin was used as loading control.
doi:10.1371/journal.pone.0050469.g006
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200c in the epithelial, doxorubicin sensitive and miR-200c highly
expressing cell line BT474. As expected, inhibition of miR-200c in
BT474 resulted in cells that were significantly more resistant to
doxorubicin treatment. Second, we overexpressed miR-200c in
the mesenchymal, doxorubicin resistant and miR-200c negative
cell line MDA-MB 436. Accordingly, miR-200c expressing MDA-
MB 436 became significantly more susceptible to doxorubicin
treatment. Thus, we demonstrated in two different cell types that
miR-200c alone was able to regulate sensitivity to doxorubicin
confirming our findings of the Molecular Evolution Assay.
Since microRNAs are endogenously modulating gene expres-
sion either by degrading mRNA or by inhibiting translation,
biological functions of these tiny RNAs can be attributed to their
targets [6,7,8,9,42]. Howe et al. [31] have reported that TrkB is
targeted by miR-200c in breast cancer conferring anoikis re-
sistance. Moreover, Trk receptors including TrkB are essential for
the development and functioning of the nervous system by
mediating cell migration, proliferation and most notably survival.
Thereby, TrkB is signaling via PLCc, the MAP kinases or PI3K
and Akt [32]. Phosphorylation of Akt plays a pivotal role in cell
survival and anti-apoptotic signaling by phosphorylating and
thereby inhibiting pro-apoptotic factors like Bad or Caspase 9
[43,44]. The Molecular Evolution Assay of BT474 cells resulted in
a differential expression of TrkB over the cycles with a slight
increase in the second round followed by a reduction in the fourth
round. Consistent with the TrkB regulation, Akt phosphorylation
was remarkably enhanced in the second round and reduced again
in the fourth round. The discrepancy in the extent of TrkB and p-
Akt regulation can be explained by other clonal selection events
influencing the Akt survival pathway. As the Molecular Evolution
Assay is based on clonal selection processes, a linear regulation of
resistance markers, such as TrkB, p-Akt or p53 is not necessarily
expected [45]. Dependent on the particular condition of a treated
cell, such as genetic background, phase of cell cycle or extent of
DNA damage, distinct survival pathways are preferred to
circumvent chemotherapy. To ascertain the role of TrkB as
miR-200c dependent resistance factor, we overexpressed miR-
200c in the mesenchymal and doxorubicin resistant cell line
MDA-MB 436. In accordance with the increased susceptibility to
doxorubicin, TrkB protein was silenced in miR-200c overexpres-
sing cells. However, there were no differences in p-Akt levels
between pre-miR-200c and scrambled control transfected cells.
We ascribed this to a missing stimulus that might induce survival
signaling in our transfected cells. Therefore, we treated over-
expressing as well as control cells with doxorubicin for 24 hours to
activate survival signaling. Indeed, phosphorylation of Akt was
induced by doxorubicin treatment in the scrambled control
transfected cells, whereas in the pre-miR-200c transfected cells it
was blocked at basal levels comparable to untreated cells.
Because microRNAs regulate the expression of numerous target
genes [1,7,9], we assume that the down-regulation of miR-200c
promotes chemoresistance by modulating more than one target
gene. Shimono et al. [33] have reported that Bmi1, a member of
the polycomb group proteins, is targeted by miR-200c linking
breast cancer stem cells with normal stem cells. Furthermore,
Bmi1 is involved in the maintenance of stemness and in the
regulation of senescence [46,47,48]. Thereby, Bmi1 functions as
transcriptional repressor of a variety of genes including p16Ink4a
and p19Arf of the Ink4a locus. Repression of p19Arf results
downstream in the degradation of p53 by MDM2 leading to anti-
apoptotic effects [36]. Additionally, recent studies have shown that
Bmi1 promotes cisplatin and docetaxel resistance in osteosarcoma
and prostate cancer, respectively [34,35]. Thus, we investigated
Bmi1 protein expression over the rounds in the Molecular
Evolution Assay of BT474 cells and in miR-200c overexpressing
MDA-MB 436 cells. Accordingly, we showed a continuous up-
regulation of Bmi1 over the rounds in BT474 cells and a clear
down-regulation after miR-200c overexpression in MDA-MB 436
cells. Moreover, we demonstrated that p53 levels were decreased
after the fourth cycle of doxorubicin treatment which was in line
with the increased chemoresistance in the Molecular Evolution
Assay confirming our hypothesis. However, the mesenchymal and
resistant cell line MDA-MB 436 was p53 negative independent of
the miR-200c levels. This indicates that in MDA-MB 436 Bmi1
Figure 7. Model of miR-200c regulated chemoresistance.
Treatment of epithelial cells expressing miR-200c with doxorubicin
leads to clonal evolution of miR-200c low expressing and mesenchymal-
like cells. In consequence, a variety of miR-200c target genes are up-
regulated. Besides the induction of EMT by the up-regulation of the E-
Cadherin (CDH1) repressors Zeb1 and Zeb2 [41,49], this loss of miR-200c
can cause an elevation of resistance factors like TrkB and Bmi1 resulting
in enhanced cell survival. This leads to the activation of anti-apoptotic
pathways like the phosphorylation of Akt or the degradation of p53,
which can be further modulated by a complex crosstalk.
doi:10.1371/journal.pone.0050469.g007
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may mediate resistance via other pathways than p53, for instance
via the PI3K/Akt pathway [35], and that p53 might be silenced
through epigenetics, e.g. through promoter methylation. Addi-
tionally, miR-200c is a key modulator of a variety of genes which
can potentially contribute to chemoresistance. Therefore, we are
aware of the possibility that more than these two target genes
described in this study can provide different resistance mechanisms
dependent on the respective genetic background. Nevertheless,
our results demonstrate how one microRNA is able to regulate the
circuitry of many pathways to render cancer cells susceptible or
resistant to chemotherapy.
In conclusion, doxorubicin treatment of a heterogenous cancer
cell population leads to clonal evolution and selection of miR-200c
low expressing cells and subsequently to an up-regulation of
various target genes including EMT inducing repressors like Zeb1
and Zeb2 [41,49] as well as chemoresistance inducing factors like
TrkB or Bmi1 resulting in enhanced survival signaling (Figure 7).
This study is one step forward in the understanding of miR-
200c dependent regulation of chemoresistance. Furthermore, our
results provide an insight into the complex interaction network of
microRNAs and their numerous target genes highlighting the
challenges in cancer therapy and supporting strategies utilizing
microRNA-modulating anticancer drugs in the future.
Supporting Information
Figure S1 Expression of miR-200 family members in
BT474 cells. miR-200 family screen in BT474 cells. Quantitative
RT-PCR was performed to analyze the levels of miR-141, miR-
200a, miR-200b, miR-200c and miR-429. The expression of the
respective microRNA was normalized to miR-191 as reference
and depicted as ratio.
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